Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centre for Mendelian Genomics, |
RCV001198186 | SCV001369056 | uncertain significance | Peripheral neuropathy-myopathy-hoarseness-hearing loss syndrome | 2019-07-23 | criteria provided, single submitter | clinical testing | This variant was classified as: Uncertain significance. The available evidence on this variant's pathogenicity is insufficient or conflicting. The following ACMG criteria were applied in classifying this variant: PM2. |
Al Jalila Children’s Genomics Center, |
RCV001732070 | SCV001984565 | uncertain significance | Autosomal dominant nonsyndromic hearing loss 4A | 2020-02-11 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004033478 | SCV005014814 | uncertain significance | Inborn genetic diseases | 2022-03-31 | criteria provided, single submitter | clinical testing | The c.5978A>C (p.H1993P) alteration is located in exon 41 (coding exon 40) of the MYH14 gene. This alteration results from a A to C substitution at nucleotide position 5978, causing the histidine (H) at amino acid position 1993 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |